Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01074970 · ClinicalTrials.gov registry record · Phase 2
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
A Phase 2 study, sponsored by Hoosier Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
NCT01074970 is a Phase 2 study that has completed, run by Hoosier Cancer Research Network. The registered enrollment target is 135 participants.
The verdict
NCT01074970, a Phase 2 study, has completed, sponsored by Hoosier Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate 2-year disease-free survival in this patient population treated with single agent cisplatin and patients treated with cisplatin in combination with Rucaparib following preoperative chemotherapy. Side effects and tolerability of this treatment in patients with residual disease following preoperative chemotherapy will also be observed and characterized.
Interventions
- DRUG Cisplatin
- DRUG Rucaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2010-02 |
| Est. Completion | 2018-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01074970
The ClinicalTrials.gov registry entry for NCT01074970 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoosier Cancer Research Network, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cisplatin is the first listed.
NCT01074970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01074970 about?
NCT01074970 is a clinical study titled "PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations". The purpose of this trial is to evaluate 2-year disease-free survival in this patient population treated with single agent cisplatin and patients treated with cisplatin in combination with Rucaparib following preoperative chemotherapy. Side effects and tolerability of this treatment in patients with...
What is the current status of trial NCT01074970?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2010-02. Estimated completion is 2018-12-15.
What interventions are being tested in trial NCT01074970?
The interventions under investigation include: Cisplatin (DRUG), Rucaparib (DRUG).
Who is sponsoring clinical trial NCT01074970?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.